Health body opens market engagement on pathology diagnostics framework
A health sector buyer is consulting suppliers on a national framework for in‑vitro diagnostics, point of care testing and pathology services.
A health sector buyer is consulting suppliers on a national framework for in‑vitro diagnostics, point of care testing and pathology services.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
A national market engagement launched on 15th April 2026 by Supply Chain Coordination Limited sets out plans for an NHS Supply Chain Pathology Services Framework covering in‑vitro diagnostic devices, point of care testing products and a broad range of pathology services. The work could reshape how advanced diagnostics, including genetic and molecular tests, reach laboratories and near‑patient settings across the health service in the coming years.
The Prior Information Notice confirms that NHS Supply Chain is seeking suppliers for a national framework agreement. The focus spans three broad areas:
The notice indicates that interested parties are invited to engage through a webinar and provide feedback. That combination of early signalling and structured discussion suggests the buyer wants to test market appetite and refine the eventual specification before moving to a formal tender.
Although detailed lot structures and volumes are not yet set out, the scope points to a framework that could bring together devices, consumables and service elements across disciplines. By explicitly flagging both IVD devices and pathology services, the buyer is opening the door to technologies ranging from routine clinical chemistry through to more specialised genetic and molecular testing.
For laboratories, pathology networks and diagnostics manufacturers, a national framework of this kind matters because it can become the main commercial route into large parts of the health system. It also shapes how standardisation, quality assurance and data requirements are set across equipment, reagents and service provision.
Across recent procurements, pathology buyers have been moving away from stand‑alone product purchases towards integrated solutions, managed services and connected testing platforms. The inclusion of POCT products and pathology services alongside IVD devices in the proposed framework fits that direction.
In January 2026, the Business Services Organisation signalled this shift through its Market Engagement for POCT Services. That preliminary exercise looked at a managed service contract for INR and handheld blood gas testing, rather than simple kit supply, underlining how service models, maintenance and quality processes are becoming central to POCT deals.
Local authorities running NHS Health Check programmes have taken a similar route. In November 2025, North Northamptonshire Council issued a contract notice for NHS Health Checks POCT Equipment, seeking consumables, analysers, maintenance support, quality assurance materials and training in one package. West Northamptonshire Council followed in January 2026 with a POCT Equipment and Support Framework for similar programmes.
Connectivity is another clear pressure point. In March 2026, the US Department of Defense went to market for Middleware for Point of Care Testing at Naval Medical Center Camp Lejeune. The requirement is a middleware solution that transmits POCT results into the laboratory information system, highlighting how near‑patient devices now have to sit within wider digital infrastructures rather than operate in isolation.
UK hospital pathology departments are also exploring long‑term, integrated arrangements for equipment. In February 2026, Gloucestershire Hospitals NHS Foundation Trust invited suppliers to engage on a Pathology Managed Equipment Service Engagement. That preliminary work is aimed at a managed equipment service across the trust’s pathology provision, again moving beyond transactional purchasing.
Seen against this backdrop, the NHS Supply Chain Pathology Services Framework is likely to draw strong interest from suppliers who can combine devices, connectivity and service support. The webinar‑based engagement offers a chance for those suppliers to explain how they integrate hardware, software and services in practice.
Recent notices show how digital pathology and molecular diagnostics are moving from niche projects to routine investment. In December 2025, University Hospitals Plymouth NHS Trust issued a Prior Information Notice for a Digital Histopathology Service Procurement. The trust outlined plans for an integrated end‑to‑end digital histopathology service with AI diagnostic support and NHS reporting, focused on the prostate cancer pathway.
Elsewhere in Europe, pathology services are being rebuilt around digital imaging. In March 2026, Region Midtjylland in Denmark published a contract notice for a Digital Pathology Solution, aiming for fully digitalised workflows for microscopy and diagnostic evaluation of tissue samples in three pathology departments.
Investment in molecular and genomic capacity is also accelerating. In January 2026, Masarykův onkologický ústav sought a Next Generation Sequencer for Diagnostics, specifying a mid‑capacity sequencer for in‑vitro diagnostics along with related services and consumables. In February 2026, Spitalul Judetean de Urgenta Alba Iulia tendered for Equipment for Pathological Anatomy, including a PCR system and an ultra freezer for a cancer diagnostic laboratory.
Sequencing infrastructure needs matching reagents and consumables. In March 2026, Szegedi Tudományegyetem released a contract notice for Molecular Diagnostic Test Consumables, divided into three lots tied to specific devices. In the US, the Department of Veterans Affairs conducted market research in March 2026 on Cepheid Reagents Procurement Research for GeneXpert systems at Cincinnati VA Medical Center, again emphasising the importance of secure reagent supply chains.
Other buyers are modernising histopathology hardware. In October 2025, Wojewódzki Szpital Zespolony im. dr. Romana Ostrzyckiego w Koninie sought Pathomorphological Diagnostics Equipment, while in November 2025 Międzyleski Szpital Specjalistyczny w Warszawie launched a Pathological Diagnostics Equipment Purchase aligned with oncology strategies.
Against this wider picture, a national NHS Supply Chain framework that brings together IVD devices, POCT products and pathology services is notable. It has the potential to provide a single commercial structure through which laboratories can access both traditional platforms and newer digital, molecular and near‑patient technologies.
Framework agreements are also being used to support resilience, standardisation and research activity in diagnostics. In March 2026, the UK Health Security Agency launched the UKHSA Diagnostic and Research Framework, an open framework split into two lots: diagnostics goods and services, and research and development. That structure shows how national bodies are seeking flexible purchasing routes that can support both routine operations and innovation.
Regional and local service contracts follow a similar logic. In November 2025, Etelä‑Pohjanmaan hyvinvointialue in Finland set out a Pathology Services Contract for specialty medical services and diagnostic sample services, with an initial term and annual extension options, underlining the desire for continuity.
Consumables and logistics are also attracting closer attention. In April 2026, East Suffolk and North Essex NHS Foundation Trust began Pathology Consumables Market Engagement on bespoke labels, forms and packaging to inform future strategies and improve operational efficiency. Earlier, in October 2025, The Shrewsbury and Telford Hospital NHS Trust issued a contract notice simply titled Pathology Consumables, reflecting the continuing need to secure core supplies.
Several buyers are bundling reagents and equipment into multi‑lot frameworks. In October 2025, Azienda Sanitaria Provinciale di Messina launched a five‑year Service Supply for Clinical Pathology across 18 lots for clinical pathology units. In November 2025, SPITAL CLINIC JUDETEAN DE URGENTA BIHOR set up a framework for a wide range of reagents and consumables through its Supply of Pathological Anatomy Reagents. In December 2025, Fondazione Istituto G. Giglio di Cefalù published a Supply Contract for Laboratory Reagents combining reagents and equipment on free loan.
Within England, South Tees Hospitals NHS Foundation Trust signalled in April 2026 that it will award multiple Pathology Testing Contracts for referred testing using the Provider Selection Regime’s most suitable provider process. That illustrates how local commissioners are choosing flexible mechanisms to secure specialist testing alongside broader national arrangements.
The emerging NHS Supply Chain framework sits squarely in this landscape. By aggregating demand for IVD devices, POCT products and pathology services at national level, it could provide a consistent commercial platform while still allowing local organisations to pursue specialist or complementary arrangements where needed.
As a Prior Information Notice, the pathology framework is at an early stage. Key features such as lot structure, contract duration, pricing approaches and specific technology requirements are yet to be set out. The planned webinar and feedback process will be central to how those details are shaped.
Suppliers will be watching for signals on several fronts: the extent to which genetic and molecular testing will be explicitly covered; how digital pathology tools and connectivity solutions are treated alongside instruments and reagents; and whether managed service models will sit alongside traditional product supply.
The final design of the framework will also show how national diagnostics procurement aligns with other initiatives such as the UKHSA Diagnostic and Research Framework and local referred testing contracts. For now, the April 2026 notice is a clear indication that central coordination of pathology, IVD and POCT purchasing is set to tighten, and that supplier input at this stage could influence the shape of the market for years to come.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.